<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03311373</url>
  </required_header>
  <id_info>
    <org_study_id>PT010011</org_study_id>
    <nct_id>NCT03311373</nct_id>
  </id_info>
  <brief_title>A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010 Administered With and Without a Spacer, and With and Without Oral Charcoal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to
      Assess the Relative Bioavailability of PT010
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to
      Assess the Relative Bioavailability of PT010 Administered With and Without a Spacer, and With
      and Without Oral Charcoal
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Actual">December 15, 2017</completion_date>
  <primary_completion_date type="Actual">December 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)-Budesonide</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) per Regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)-Glycopyrronium</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) per Regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)-Formoterol</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax) per Regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 the Time of the Last Measurable Plasma Concentration (AUC0-tlast)-Budesonide</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Each treatment period is equal to assigned regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 the Time of the Last Measurable Plasma Concentration (AUC0-tlast)-Glycopyrronium</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Each treatment period is equal to assigned regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 the Time of the Last Measurable Plasma Concentration (AUC0-tlast)-Formoterol</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Each treatment period is equal to assigned regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax)-Budesonide</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Each treatment period is equal to assigned regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax)-Glycopyrronium</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Each treatment period is equal to assigned regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax)-Formoterol</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Each treatment period is equal to assigned regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞);-Budesonide</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Each treatment period is equal to assigned regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞);-Glycopyrronium</measure>
    <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
    <description>Each treatment period is equal to assigned regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞);-Formoterol</measure>
    <time_frame>24 hrs</time_frame>
    <description>Each treatment period is equal to assigned regimen</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Formulation (Regimen B or D) or Reference Formulation (Regimen A or C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen A</intervention_name>
    <description>2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure</description>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_label>Treatment Period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen B</intervention_name>
    <description>2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure</description>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_label>Treatment Period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen C</intervention_name>
    <description>2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure</description>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_label>Treatment Period 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen D</intervention_name>
    <description>2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure</description>
    <arm_group_label>Treatment Period 1</arm_group_label>
    <arm_group_label>Treatment Period 2</arm_group_label>
    <arm_group_label>Treatment Period 3</arm_group_label>
    <arm_group_label>Treatment Period 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed and dated Independent Ethics Committee (IEC)/Institutional Review Board
             (IRB)-approved Informed Consent Form (ICF) before any protocol-specific screening
             procedures are performed

          -  Male and female subjects 18 to 40 years of age, inclusive

          -  Be in good general health as determined by a thorough medical history and physical
             examination, ECG, vital signs, and clinical laboratory evaluation

          -  Non-childbearing potential (ie, physiologically incapable of becoming pregnant,
             including any female who is 2 years post-menopausal, or surgically sterile

          -  Male subjects who are sexually active must agree to use a double-barrier method of
             contraception (condom with spermicide) from the first dose of randomized study drug
             until 2 weeks after their last dose, and must not donate sperm during their study
             participation period

          -  Screening laboratory tests must be within normal range or determined to not be
             clinically significant by the Investigator.

          -  Demonstrate correct MDI administration technique

        Key Exclusion Criteria:

          -  For female subjects, a positive serum human chorionic gonadotropin (hCG) test at
             screening or a positive urine hCG at admission for any of the 4 Treatment Periods

          -  Subjects with clinically significant neurologic, cardiovascular, hepatic, renal,
             endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that
             would interfere with participation in this study

          -  Subjects who have cancer that has not been in complete remission for at least 5 years

          -  Male subjects with a trans-urethral resection of the prostate or full resection of the
             prostate within 6 months prior to screening

          -  Subjects with bladder neck obstruction or urinary retention that is clinically
             significant in the opinion of the Investigator

          -  History of substance-related disorders (with the exception of caffeine-related and
             nicotine-related disorders) within 1 year of screening

          -  History of smoking or the use of nicotine-containing products within 3 months of
             screening by self-reporting

          -  A positive alcohol breathalyzer or urine drug screen for drugs of abuse at screening
             or at the beginning of each Treatment Period

          -  Treatment with any prescription or non-prescription drugs including vitamins, herbal,
             and dietary supplements for 28 days or 5 half-lives, whichever is longer, before study
             drug use

          -  Treatment with an investigational drug within 30 days or 5 half-lives (whichever is
             longer) prior to the beginning of the screening Period

          -  Subjects with any flu-like syndrome or other respiratory infections within 2 weeks of
             drug administration or who have been vaccinated with an attenuated live virus within 4
             weeks of drug administration

          -  Any other condition and/or situation that causes the Investigator to deem a subject
             unsuitable for the study (eg, inability to medically tolerate the study procedures, or
             a subject's unwillingness to comply with study-related procedures)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul M. Dorinsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=PT010011&amp;amp;attachmentIdentifier=101b3e8b-ad61-40b9-a1b0-4edfb4c6fb48&amp;amp;fileName=PT010011_SAP__v1.0_16J_Jan_2018_Redacted_Final_PDF-A.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=PT010011&amp;amp;attachmentIdentifier=9d004324-7532-460f-8551-bfd83a9ea40d&amp;amp;fileName=PT010011_Protocol_v1.0_11Sep2017__Redacted_Final-PDF-A.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <results_first_submitted>March 27, 2020</results_first_submitted>
  <results_first_submitted_qc>June 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2020</results_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03311373/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03311373/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at a single center in the United States from November 2017 to December 2017.</recruitment_details>
      <pre_assignment_details>Elig subj. received single dose of BGF MDI (Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler) 320/28.8/9.6 μg as:
Regimen A: BGF MDI w/out spacer, w/out charcoal Regimen B: BGF MDI with spacer, w/out charcoal Regimen C: BGF MDI w/out spacer, with charcoal Regimen D: BGF MDI with spacer, with charcoal</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Regimens</title>
          <description>BGF MDI 320/28.8/9.6 μg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Discontinuation Criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.9" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)-Budesonide</title>
        <description>Maximum plasma concentration (Cmax) per Regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)-Budesonide</title>
          <description>Maximum plasma concentration (Cmax) per Regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="702.3" spread="46.4"/>
                    <measurement group_id="O2" value="452.6" spread="74.6"/>
                    <measurement group_id="O3" value="340.0" spread="117.1"/>
                    <measurement group_id="O4" value="612.0" spread="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)-Glycopyrronium</title>
        <description>Maximum plasma concentration (Cmax) per Regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)-Glycopyrronium</title>
          <description>Maximum plasma concentration (Cmax) per Regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" spread="73.3"/>
                    <measurement group_id="O2" value="19.0" spread="131.0"/>
                    <measurement group_id="O3" value="17.1" spread="181.7"/>
                    <measurement group_id="O4" value="42.1" spread="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)-Formoterol</title>
        <description>Maximum plasma concentration (Cmax) per Regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)-Formoterol</title>
          <description>Maximum plasma concentration (Cmax) per Regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="58.4"/>
                    <measurement group_id="O2" value="10.8" spread="66.3"/>
                    <measurement group_id="O3" value="8.3" spread="98.6"/>
                    <measurement group_id="O4" value="17.9" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 the Time of the Last Measurable Plasma Concentration (AUC0-tlast)-Budesonide</title>
        <description>Each treatment period is equal to assigned regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 the Time of the Last Measurable Plasma Concentration (AUC0-tlast)-Budesonide</title>
          <description>Each treatment period is equal to assigned regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1934.0" spread="54.9"/>
                    <measurement group_id="O2" value="1452.8" spread="66.0"/>
                    <measurement group_id="O3" value="823.9" spread="121.2"/>
                    <measurement group_id="O4" value="1618.5" spread="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 the Time of the Last Measurable Plasma Concentration (AUC0-tlast)-Glycopyrronium</title>
        <description>Each treatment period is equal to assigned regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 the Time of the Last Measurable Plasma Concentration (AUC0-tlast)-Glycopyrronium</title>
          <description>Each treatment period is equal to assigned regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" spread="96.4"/>
                    <measurement group_id="O2" value="48.1" spread="122.4"/>
                    <measurement group_id="O3" value="19.8" spread="325.0"/>
                    <measurement group_id="O4" value="69.2" spread="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 the Time of the Last Measurable Plasma Concentration (AUC0-tlast)-Formoterol</title>
        <description>Each treatment period is equal to assigned regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 the Time of the Last Measurable Plasma Concentration (AUC0-tlast)-Formoterol</title>
          <description>Each treatment period is equal to assigned regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="97.5"/>
                    <measurement group_id="O2" value="37.0" spread="88.7"/>
                    <measurement group_id="O3" value="8.9" spread="471.8"/>
                    <measurement group_id="O4" value="33.1" spread="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax)-Budesonide</title>
        <description>Each treatment period is equal to assigned regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax)-Budesonide</title>
          <description>Each treatment period is equal to assigned regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>h (hour)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.10" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.33" lower_limit="0.10" upper_limit="2.00"/>
                    <measurement group_id="O3" value="0.33" lower_limit="0.10" upper_limit="2.00"/>
                    <measurement group_id="O4" value="0.33" lower_limit="0.10" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax)-Glycopyrronium</title>
        <description>Each treatment period is equal to assigned regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax)-Glycopyrronium</title>
          <description>Each treatment period is equal to assigned regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>h (hour)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.03" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="4.00"/>
                    <measurement group_id="O3" value="0.03" lower_limit="0.03" upper_limit="0.67"/>
                    <measurement group_id="O4" value="0.03" lower_limit="0.03" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax)-Formoterol</title>
        <description>Each treatment period is equal to assigned regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax)-Formoterol</title>
          <description>Each treatment period is equal to assigned regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>h (hour)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="0.03" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.03" upper_limit="4.00"/>
                    <measurement group_id="O3" value="0.10" lower_limit="0.03" upper_limit="0.67"/>
                    <measurement group_id="O4" value="0.10" lower_limit="0.03" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞);-Budesonide</title>
        <description>Each treatment period is equal to assigned regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞);-Budesonide</title>
          <description>Each treatment period is equal to assigned regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2132.1" spread="40.9"/>
                    <measurement group_id="O2" value="1491.8" spread="64.4"/>
                    <measurement group_id="O3" value="823.9" spread="121.2"/>
                    <measurement group_id="O4" value="1806.2" spread="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞);-Glycopyrronium</title>
        <description>Each treatment period is equal to assigned regimen</description>
        <time_frame>Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 12 and 24 h post-dose</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞);-Glycopyrronium</title>
          <description>Each treatment period is equal to assigned regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="49.6"/>
                    <measurement group_id="O2" value="65.9" spread="44.7"/>
                    <measurement group_id="O3" value="15.2" spread="54.5"/>
                    <measurement group_id="O4" value="39.2" spread="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞);-Formoterol</title>
        <description>Each treatment period is equal to assigned regimen</description>
        <time_frame>24 hrs</time_frame>
        <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Regimen B</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
          </group>
          <group group_id="O2">
            <title>Regimen A</title>
            <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
          </group>
          <group group_id="O3">
            <title>Regimen C</title>
            <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
          </group>
          <group group_id="O4">
            <title>Regimen D</title>
            <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-∞);-Formoterol</title>
          <description>Each treatment period is equal to assigned regimen</description>
          <population>PK Population: All subjects in the Safety Population for whom at least one of the primary PK parameters for a given analyte could be calculated and who had no important protocol deviations thought to impact the analysis of the PK data.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" spread="37.1"/>
                    <measurement group_id="O2" value="62.7" spread="62.2"/>
                    <measurement group_id="O3" value="62.6" spread="55.0"/>
                    <measurement group_id="O4" value="62.0" spread="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of administration of the first dose of study drug to the time of the follow-up telephone call, study termination, or study exit up to a total of approximately 12 weeks.</time_frame>
      <desc>Serious Adverse Events were collected from the time the subject signed informed consent throughout the treatment period and up to approximately 13 weeks, which includes screening and follow up (5-7 day period after study drug).</desc>
      <group_list>
        <group group_id="E1">
          <title>Regimen B</title>
          <description>BGF MDI 320/28.8/9.6 μg with a spacer device and without charcoal</description>
        </group>
        <group group_id="E2">
          <title>Regimen A</title>
          <description>BGF MDI 320/28.8/9.6 μg without spacer device and without charcoal</description>
        </group>
        <group group_id="E3">
          <title>Regimen C</title>
          <description>BGF MDI 320/28.8/9.6 μg without a spacer device and with charcoal</description>
        </group>
        <group group_id="E4">
          <title>Regimen D</title>
          <description>BGF MDI 320/28.8/9.6 μg with a spacer device and with charcoal</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pearl Therapeutics, Inc.</name_or_title>
      <organization>Pearl Therapeutics, Inc.</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

